NCT05333302View on ClinicalTrials.gov

Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 26, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions
B-cell Acute Lymphoblastic LeukemiaLymphoblastic B-Cell Lymphoma
Interventions
BIOLOGICAL

CD19 CAR-T-cells

One dose of CD19 CAR-T cells (1\*10e6 CAR+ T-cells/kg) by intravenous infusion.

DRUG

Tocilizumab

Before 1h of CAR-T cells infusion a patient receive tocilizumab (8 mg/kg).

Trial Locations (1)

223053

RECRUITING

Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk

All Listed Sponsors
lead

Belarusian Research Center for Pediatric Oncology, Hematology and Immunology

OTHER

NCT05333302 - Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma | Biotech Hunter | Biotech Hunter